Roche sets bar in early lymphoma treatment with Polivy study results

Roche on Monday said its cancer drug Polivy combined with a common chemotherapy regimen held lymphoma in check for longer than the standard drugs alone in patients who had not been previously treated. According to the Swiss pharma, the drug is the first treatment shown to improve outcomes in these patients in 20 years.